Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. ViRexx was originally founded, as AltaRex, in November 1995 by Dr Antoine Noujaim, formerly President of Biomira
Research Inc, and a team of collaborators to discover and develop anticancer immunotherapeutics based on the B43
antibody (Ab) research project originally undertaken by Biomira Research (known as the OvaRex MAb Program). In
November 1995, AltaRex acquired certain components of the OvaRex MAb Program and the OvaRex MAb tradename
and trademark from Biomira Inc and Biomira Research and entered into an exclusive licensing agreement with Biomira
pursuant to which it acquired the exclusive worldwide right to use, develop, manufacture and commercialise (for antiidiotype
induction therapy applications) products based on the B43 Ab.